Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
GAITHERSBURG, Md., Oct. 13, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Dawson James Securities 3rd Annual Small Cap Growth Conference on Thursday, October 19, 2017 at 9:00 a.m. Eastern time. The conference will be held at the Wyndham Grand Hotel in Jupiter, Florida on October 18-19, 2017.
In addition, Mr. Jones will participate on a panel discussion titled "The Convergence of Artificial Intelligence and Healthcare: New Developments in Precision Medicine” on Wednesday, October 18, 2017 at 5:00 p.m. Eastern time.
To listen to the corporate presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An archived webcast of the presentation will also be available on OpGen’s website for a period of time.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. For more information, please visit www.opgen.com.
OpGen®, Acuitas®, Acuitas Lighthouse® and QuickFISH® are registered trademarks of OpGen, Inc.
OpGen Contact:
Michael Farmer
Sr. Director, Marketing
240-813-1284
[email protected]
[email protected]
Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]
or
Bruce Voss
310-691-7100
[email protected]
